Dr. Schlumbrecht on Remaining Challenges in Uterine Leiomyosarcoma

Video

In Partnership With:

Matthew P. Schlumbrecht, MD, discusses remaining challenges in uterine leiomyosarcoma.

Matthew P. Schlumbrecht, MD, associate professor and co-director of Cancer Prevention and Control, Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses remaining challenges in uterine leiomyosarcoma.

Historically, uterine leiomyosarcoma has been a difficult tumor to treat, explains Schlumbrecht. Studies have not definitively shown that up front chemotherapy is effective. Additionally, a limited number of chemotherapy and targeted therapy has shown activity in the recurrent setting.

As such, the prognosis for women with this disease remains poor, says Schlumbrecht.

Going forward, identifying predictive biomarkers and underlying genetic mutations may help the field understand which patients are more likely to respond to treatment, concludes Schlumbrecht.

Related Videos
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP